Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma

A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yige, Saraswat, Aishwarya, Wei, Zenghui, Agrawal, Manas Yogendra, Dukhande, Vikas V., Reznik, Sandra E., Patel, Ketan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308940/
https://www.ncbi.nlm.nih.gov/pubmed/34371697
http://dx.doi.org/10.3390/pharmaceutics13071005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308940/
https://www.ncbi.nlm.nih.gov/pubmed/34371697
http://dx.doi.org/10.3390/pharmaceutics13071005

Ejemplares similares